Prophylactic & Therapeutic Vaccines
EpitoGenesis, Inc.
EpitoGenesis, Inc. was established in 2008, by Ms. Shohre Golestani. The company’s flagship patented technology is based on the synergy between 3 dietary supplement/food-grade molecules that formulated together as a micro-emulsion enhance the immune response in an antigen-specific or an antigen-unspecific manner. This formulation can be used to produce vaccines or used as a dietary supplement to be consumed daily.
Years Of Research Experience
EpitoGenesis, Inc.
About EpitoGenesis, Inc.
Prophylactic & Therapeutic Vaccines
EpitoGenesis, Inc. is a biotechnology company, which was established in November of 2008, to design and develop all-natural efficacious immune enhancing adjuvants and delivery systems for prophylactic and therapeutic vaccines with a strong emphasis on safety. Our goal is to eliminate vaccination side effects such as site of injection pain and swelling, fever, etc.
SBIR Awards Won
Field Experts
Patents
Who We Are
Management & Advisor Board
Vaccines are the single most cost-effective medical interventions. Vaccines have eliminated many infectious diseases completely which only decades ago caused serious morbidity and mortality.
Who We Are
Our passion for creating meaningful change for clients is what sets us apart. Our team works tirelessly in order to bring you a better tomorrow.
Who We Are
Our passion for creating meaningful change for clients is what sets us apart.
Advanced Solutions
For every simple solution released into the market, there’s a great amount of technology that must be either invented or adapted for that purpose, and Epitogenesis is no exception.
Innovative Technology
Vaccines are the single most cost-effective medical interventions. Vaccines have eliminated many infectious diseases completely which only decades ago caused serious morbidity and mortality.
Since the days of Luis Pasteur, over a century ago, vaccine developers have continued to focus on live attenuated viruses and bacteria and chemical structures that induce strong pro-inflammatory immune responses. However, these very same responses are responsible for unwanted side effects.
News And Events
Media & Press Updates
Continue reading and learn all there is to know about the smart tech behind our successful Biotechnology Startup.
Please see our peer-reviewed publications under the NEWS page.
June 2013
EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to develop a vaccine against vaginal …
October 2010
EpitoGenesis enters into an agreement with Children’s Hospital Oakland Research Institute on a collaborative project to develop a vaccine against sexual transmission of Chlamydia trachomatis.